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Despite great technical advances over the last decades, 
cardiac pacing is still associated with a significant rate of 
complications mostly ascribed to the pacing leads.1 Leads 
are susceptible to mechanical stress, whether transvenous 
or epicardial, and constitute the pacing component most 
prone to failure; they are the major contributor to compli-
cations, may cause vascular obstruction, and other late 
complications, such as mechanical failure and infection, 
whereby extraction is required with its attendant dire 
consequences. Implantation of a pacemaker in young 
patients exposes them to high risk of subsequent lead 
complications, and when failed leads are replaced without 
extraction, the presence of multiple endocardial leads 
may cause major vascular morbidity. New devices for bi-
ventricular or bifocal pacing to effect cardiac resynchro-
nization therapy (CRT) incorporating 3 leads are associa-
ted with even more problems. Hence, there came about a 
resurge of interest in the technology of leadless pacing.  
The first totally self-contained leadless pacemaker 
system was proposed by Spickler back n 1970 using a 
device powered by mercury-zinc and nuclear power that 
was successfully tested in animals.2 Almost 30 years 
later, Gotto et al 3 tested an automatic power-generating 
system (AGS) which converts kinetic into electric energy 
for quartz watches as a power source for cardiac 
pacemakers. They could demonstrate that the circuit 
generated pulses of 0.5 ms width at 1 Hz (60 pulses/min). 
The voltage of the AGS was maintained at 1.6 V while it 
was being charged by the accelerations. The generator 
supplied pulses of 0.75 V, 1.47 mA via a 510-ohm load. 
With fully charged AGS, the generator was also used to 
pace a mongrel dog's heart at 140 beats/min for 60 min. 
During pacing, the AGS supplied 420 mJ to the circuit 
and the cardiac muscle. The AGS was placed on the right 
ventricular wall of the dog under anesthesia. Energy of 80 
mJ is stored in a capacitor by the heart beating at ~ 200 
beats/min for 30 min. Thus, the AGS generated 13 microJ 
per heart beat. This result suggested that the AGS could 
supply enough energy for use in a cardiac pacemaker.  
Several years later, Echt at al 4 explored the feasibility 
and safety of a technology enabling cardiac pacing 
without leads in an acute porcine model. The system 
comprised an ultrasound transmitter delivering energy 
from the chest wall to a receiver-electrode in contact with 
the myocardium that then converted the ultrasound 
energy to electrical energy sufficient to pace. In 
feasibility studies, the receiver-electrodes were attached 
to the tip of a catheter to facilitate intracardiac positioning 
at pacing sites. In safety studies, ultrasound energy was 
transmitted to both chest walls, and histopathologic 
examinations were performed to evaluate bioeffects due 
to ultrasound energy transmission. In feasibility studies, 
direct and ultrasound-mediated electrical pacing was 
demonstrated at 30 sites in the right atrium, right ventricle 
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(RV), and left ventricle (LV), at direct electrical pacing 
outputs of 1.4+0.6 V and ultrasound-mediated electrical 
pacing outputs of 1.8+0.9 V. Using 2 receiver-electrode 
catheters, biventricular pacing could be demonstrated. 
Microscopic evaluation revealed no evidence of 
mechanical or thermal bioeffects. 
Wieneke et al5 developed a temporary leadless 
pacemaker system based on induction technology and 
tested its feasibility and safety in a pig model. The device 
included a transmitter unit implanted subcutaneously at 
the level of the heart and an endocardial receiver unit 
implanted at the apex of the RV. The transmitter unit was 
used as a generator of alternating magnetic field 
converted into a voltage pulse by the receiver unit. 
During testing, an alternating magnetic field of about 
0.5mT was generated by the transmitter unit at a distance 
of 3 cm. Voltage pulses with a pulse width of 0.4 ms and 
voltage amplitude of 0.6–1.0 V were generated. These 
pulses were finally able to reliably stimulate the heart. 
The same group later in a goat model demonstrated that 
for any given endocardial position of the receiver unit, up 
to a distance of 10 cm between the subcutaneous 
transmitter and the receiver unit, reliable pacing using 
induction could be obtained.6 Energy consumption was 
mainly determined by distance and pacing threshold. In 
anatomically important distances up to 6 cm, energy 
consumption remains within reasonable limits.  
Lee et al7 reported their experience with leadless 
cardiac pacing in 10 patients with use of externally 
delivered ultrasound which provided energy that was 
transformed into an electrical stimulus by a specially 
fabricated transducer positioned at the myocardial 
surface. The authors illustrated the potential for 
ultrasonic energy transmission to be “directed” at a 
particular cardiac chamber, the LV, and to be transformed 
into electrical energy of sufficient magnitude to pace 
relatively sick hearts. Ultrasound-mediated pacing was 
successful in all patients. The acoustic window validated 
by computed tomography was predicted by transthoracic 
echocardiography. The study demonstrated, using a line-
powered ultrasound generator, the feasibility of 
ultrasound-based pacing in patients with severe LV 
dysfunction (ejection fraction 29%+5%). The longer-term 
goal would be to facilitate targeting an “optimal” LV 
pacing site for application of CRT.  
Defaria Yeh et al8 also tested temporary leadless 
cardiac pacing using ultrasound energy in patients with 
NYHA class III or IV heart failure symptoms & LV 
ejection fraction ≤35%. An implantable LV stimulation 
system transferred energy from a subcutaneous 
transmitter to an endocardial receiver through tissue free 
of interfering lung or rib (‘acoustic window’). They used 
echocardiography to evaluate acoustic window locations 
and sizes to determine the implant site for a transmitter. 
Among 42 patients, at least one adequate acoustic 
window was identified in 41. Patients with ischemic 
cardiomyopathy compared with non-ischemic cardiomyo-
pathy had smaller heart size but larger acoustic windows 
in the right lateral and standing positions.  
According to Wang et al,9 LV endocardial leadless 
pacing (LVLEP) using energy transfer from an ultrasound 
transmitter to an endocardially implanted receiver to 
stimulate the heart may offer some potential advantages. 
These may include greater choice of LV lead positions, 
possibly more rapid LV activation, lower capture 
thresholds compared with those obtained via the coronary 
sinus, reduced risk of phrenic nerve stimulation, superior 
stability of an active fixation endocardial receiver 
electrode, perhaps even less arrhythmogenic pacing, and 
finally elimination of lead-related complications, 
compared with conventional CRT implantation.  
A novel implantable cardiac pacing system based on 
this concept was recently developed for treatment of heart 
failure by EBR Systems10 & Cambridge Consultants11 
(Wireless Cardiac Stimulation-LV System, WiCS®-LV, 
EBR Systems, Inc., Sunnyvale, CA, USA) and a clinical 
trial using the WiCS®-LV system is ongoing in Europe. 
The trial, entitled Wireless Stimulation Endocardially for 
CRT (WiSE-CRT), is evaluating the safety and feasibility 
in 100 patients with heart failure who are candidates for 
CRT. In the WiSE-CRT study, the receiver electrode 
catheter is positioned in the LV via a femoral arterial 
sheath using the retrograde transaortic approach.12 On 
May 3, 2011, EBR Systems announced the first human 
implants of the WiCS® Wireless Cardiac System.  
Able to pace the heart through wireless transmission 
of energy, the WiCS system consists of a leadless 
electrode (receiver) acting as an energy harvester and a 
transmit transducer array, which is an ultrasonic pulse 
generator. Piezoelectric components are ideal for use in 
electromechanical transducers and were supplied by 
Morgan Technical Ceramics (MTC, Bedford, Ohio, USA) 
to manufacture the two key components to the system, the 
transmitter and the receiver, helping EBR Systems to 
maximize the energy efficiency of the WiCS device and 
prolong the life of the device out to 3 years.  
LVLEP may also have some potential disadvantages, 
including variable energy transfer efficiency with 
different energy transfer modes (e.g. ultrasound vs 
alternating magnetic field vs radiofrequency-RF),5,7,9 
complex technology with regards to ability of leadless 
pacing systems to detect intrinsic events and inhibit 
pacing output when necessary, and potentially worrisome 
external electromagnetic interference with the devices.  
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At present, EBR Systems is not the only company 
working on leadless pacemakers. The North Dakota State 
University (NDSU) Research Foundation, NanoStim with 
St. Jude Medical, and Medtronic have also developed or 
are developing their leadless pacing system. NDSU 
(http://www.ndsuresearchfoundation.org)13 has developed 
an innovative self-organizing, adaptive, wireless multi-
electrode cardiac pacing system, where wireless 
electrodes communicate with each other and determine 
optimal heart stimulus pattern. Electrodes harvest energy 
from an externally placed can, which emits RF energy 
and can send commands to the electrodes. Sensors (micro 
electro-mechanical systems-MEMS accelerometers) 
embodied in each wireless electrode sense movement in 
the heart and communicate information to the network of 
connected electrodes. The electrodes work together to set 
an optimal pattern for stimulating regions of the heart to 
achieve an optimal cardiac output.  
Nanostim (Milpitas, CA, USA)14 is also developing a 
miniaturized leadless pacemaker system for St. Jude 
Medical. Their primary battery uses beta-voltaic 
technology, promising a greater than 5-year longevity of 
the device. The company announced on 20/12/2012, the 
first successful implants of their leadless pacemaker in 11 
patients in Prague, recruited in the LEADLESS study, 
conducted in 8 centers in Europe, and designed to 
examine the safety and effectiveness of a totally self-
contained, leadless pacemaker system. Nanostim utilizes 
a catheter-based approach via the femoral vein delivering 
the leadless pacemaker directly into the RV.  
Medtronic is also developing a leadless pacemaker. A 
miniaturized self-contained fully implantable pacing 
device working without pacing leads can be inserted via a 
catheter. Still in the research phase, Medtronic claims to 
have already created the majority of necessary 
components for the tiny pacemaker, including circuit 
board, oscillator, capacitor, memory, and wireless 
telemetry so that the device can communicate with 
external monitoring devices. The only thing missing is a 
power source. Some prototypes of miniscule pacing 
devices have already been announced and displayed at 
conferences (Figure). If eventually successful, pacemaker 
miniaturization will be a major accomplishment that can 
lower the risks & improve the benefits of pacing devices.  
 
Conclusion 
 Although leadless pacing is indeed attractive and has 
the potential to reduce pacing complications, further 
development and clinical evidence of feasibility and 
efficacy will be required before it is clinically applied. 
However, these are complex systems and considerable 
technical difficulties, & bureaucratic obstacles will have 
to be overcome for the ultrasound and other induction 
systems to be clinically viable. Self-powered contained, 
fully-implantable systems are more likely to become 
clinically useful if they have acceptable longevity, and if 
the device can be retrieved at the time of replacement. 
 For self-contained fully implantable systems, the most 
challenging engineering step seems to be power, which is 
a fundamental & crucial part of the pacemaker. Certainly 
there will need to be several studies to be conducted 
before the FDA could approve the miniature pacemaker 
for general use. It may be optimistic to estimate that the 
device could possibly be on the market in the next 5 years 
provided that engineering and regulatory demands have 
been fulfilled by then. Investigators are also working on 
MRI compatible leadless pacemaker devices.15  
 
Figure. A self-contained miniature 
prototype of an active fixation 
leadless pacing device that is fully 
implantable via a steerable catheter 
delivery system (source: 
http://spo.escardio.org/eslides/view.aspx?
eevtid=40&fp=318)  
  
REFERENCES 
1. Trohman RG, Kim MH, Pinski SL. Cardiac pacing: the state of the 
art. Lancet 2004;364(9446):1701-1719. 
2.  Spickler J, Rasor N, Kezdi P, Misra S, Robins K, LeBoeuf C. 
Totally self-contained intracardiac pacemaker. J Electrocardiol 
1970;3:325–31. 
3. Goto H, Sugiura T, Harada Y, Kazui T. Feasibility of using the 
automatic generating system for quartz watches as a leadless 
pacemaker power source. Med Biol Eng Comput 1999;37:377-380. 
4.  Echt DS, Cowan MW, Riley RE, Brisken AF. Feasibility and 
safety of a novel technology for pacing without leads. Heart 
Rhythm 2006;3:1202-1206.  
5.  Wieneke H, Konorza T, Erbel R, Kisker E. Leadless pacing of the 
heart using induction technology: a feasibility study. Pacing Clin 
Electrophysiol 2009;32:177-183.  
6. Wieneke H, Rickers S, Velleuer J, et al. Leadless pacing using 
induction technology: impact of pulse shape and geometric factors 
on pacing efficiency. Europace Epub 2012 Oct 1. 
7. Lee KL, Tse H-F, Echt DS, et al. Temporary leadless pacing in 
heart failure patients with ultrasound-mediated stimulation energy 
and effects on acoustic window. Heart Rhythm 2009;6:742–748. 
8. DeFaria Yeh D, Lonergan KL, Fu D, Yeh RW, Echt DS, Foster E. 
Clinical factors and echocardiographic techniques related to the 
presence, size, and location of acoustic windows for leadless 
cardiac pacing. Europace 2011;13:1760-1765.  
9. Wang HX, Li XF, Zhang H, Sun S. Left ventricular endocardial 
leadless pacing brings new hope to patients with heart failure. Int J 
Cardiol 2012 Nov 17.  
10. http://www.ebrsystemsinc.com/about_us  
11. http://www.cambridgeconsultants.com/news/pr/release/6/en  
12. http://clinicaltrials.gov/show/NCT01294527  
13. http://www.ndsuresearchfoundation.org/images/pdf/RFT-
338%20Flyer%20III.pdf  
14.http://www.linkedin.com/company/nanostim-
inc?trk=top_nav_home  
15. http://ip.com/patfam/en/43781178  
